Skip to main content

Table 2 Treatment-emergent AEs occurring in ≥10% of patients in either ADT group (safety sample)

From: Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study

AE, % Bupropion plus aripiprazole (n = 46) SSRI/SNRI plus aripiprazole (n = 242)
Fatigue 26.1 23.6
Somnolence 21.7 18.2
Akathisia 17.4 23.6
Headache 17.4 15.3
Increased appetite 15.2 11.2
Insomnia 15.2 15.7
Arthralgia 13.0 3.3
Irritability 13.0 3.7
Middle insomnia 13.0 2.5
Upper respiratory tract infection 13.0 10.7
Erectile dysfunction 12.5 2.6
Anxiety 10.9 11.2
Asthenia 10.9 3.7
Back pain 10.9 5.4
Dry mouth 10.9 10.3
Nausea 10.9 11.6
Restlessness 10.9 12.4
Salivary hypersecretion 10.9 3.7
Tremor 10.9 8.7
Dizziness 8.7 10.3
Weight increased 8.7 19.0
  1. ADT, antidepressant treatment; AE, adverse event; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.